SINTX Technologies

SINT · NASDAQ

$1.72+$0.03 (+1.78%)TodayMarket closed · Oct 21, 7:04 AM ET

Prev close $1.69

SINT analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $9.69 (+463.4% upside)

Low: $6.06
Now: $1.72
High: $13.13

Upgrades and downgrades

The latest rating actions, newest first

SINT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Oct 1, 2026	Maintains	Buy	$12.00 → $12.50	28%
Maxim Group	Jun 4, 2026	Initiates	Buy	$6.00	26%
HC Wainwright & Co.	May 20, 2026	Maintains	Buy	$10.00	36%
HC Wainwright & Co.	Apr 13, 2026	Initiates	Buy	$10.00	36%
Ascendiant Capital	Apr 8, 2026	Maintains	Buy	$16.00 → $12.00	28%
Ascendiant Capital	Dec 8, 2025	Maintains	Buy	$25.00 → $16.00	28%

The case for and against

Updated Oct 21, 2026

Bull case

SINTX Technologies is building a more commercial, higher-upside orthopedic and biomaterials business through its silicon nitride platform, with the June 2025 acquisition of SiNAPTIC adding six differentiated foot and ankle implant systems and expanding its addressable market. The October 2025 FDA 510(k) clearance, December 2025 Evonik manufacturing agreement, and March 2026 first-in-human procedure provide clear validation of product readiness, clinical traction, and partnership momentum. Financially, 1Q26 revenue of $0.38M grew 3% y/y, while continuing operations rose 46% and product revenue increased 32%, suggesting early commercialization progress despite the still-small revenue base and significant upside potential.

Bear case

SINTX Technologies is challenged by weak profitability and fragile liquidity, as Q2 2026 revenue was only $0.5 million while net loss widened to $3.6 million, or $(0.75) per share, with no Q2 guidance provided. The company’s outlook is further pressured by the need for surgeon adoption, commercialization execution, regulatory approvals, reimbursement, and partnership development, all of which remain uncertain and capital intensive. With balance sheet risk and explicit going-concern risk cited alongside competitive pressure and dependence on future pipeline success, the fundamental case remains highly speculative.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.